AUL
SRPT icon

AlphaGrep UK Ltd’s Sarepta Therapeutics SRPT Stock Holding History

AlphaGrep UK Ltd’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$249K Buy
+11,449
New +$222K 0.07% 600

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaGrep UK Ltd's SRPT Position: Q1 2026 in Review

AlphaGrep UK Ltd opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 11,449 shares worth $249K. The stake represents 0.07% of the portfolio and ranks #600 among its holdings.

342 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • AlphaGrep UK Ltd held 11,449 shares of Sarepta Therapeutics worth $249K as of Q1 2026.
  • Sarepta Therapeutics was a new AlphaGrep UK Ltd position in Q1 2026.
  • Sarepta Therapeutics made up 0.07% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #600 holding.
  • 342 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.